date,title,source
Oct-24-18,Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer,PR Newswire
Nov-07-18,Myovant Strengthens Management Team and Adds New Directors to the Board,PR Newswire
Nov-08-18,"Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018",PR Newswire
Nov-14-18,"Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences  Renewed Outlook, Key Drivers of Growth",GlobeNewswire
Nov-15-18,Myovant Sciences to Participate in Two Upcoming Investor Conferences,PR Newswire
Dec-20-18,Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference,PR Newswire
Jan-02-19,Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference,PR Newswire
Jan-11-19,Andreas Halvorsen Plunges Into Biotech Company Myovant Sciences,GuruFocus.com
Feb-07-19,Myovant Sciences: Fiscal 3Q Earnings Snapshot,Associated Press
Feb-07-19,"Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018",PR Newswire
Feb-08-19,4 Disruptive Healthcare Stocks You've Never Heard Of,Motley Fool
Feb-21-19,Myovant- &quot;Value Creation&quot; in Cancer Treatment,MoneyShow
Mar-05-19,Myovant Sciences to Present at Upcoming Investor Conferences,PR Newswire
May-02-19,Heres What Hedge Funds Think About Myovant Sciences Ltd. (MYOV),Insider Monkey
May-13-19,"Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids",GlobeNewswire
May-14-19,Myovant Shares Slide Despite Positive Late-Stage Data For Menstrual Bleeding Drug,Benzinga
May-14-19,Myovant stock up 1.6% after Phase 3 trial meets endpoints,MarketWatch
May-14-19,Myovant Sciences' uterine fibroids combo therapy meets main goal in study,Reuters
May-14-19,"Introducing Myovant Sciences (NYSE:MYOV), The Stock That Dropped 23% In The Last Year",Simply Wall St.
May-14-19,Myovant Sciences' uterine fibroids combo therapy meets main goal in study,Reuters
May-14-19,Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids,GlobeNewswire
May-15-19,"Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups &amp; Other Updates",Zacks
May-20-19,"Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea",American City Business Journals
May-29-19,Myovant Sciences Announces $100 Million Public Offering of Common Shares,GlobeNewswire
